MCID: SFT003
MIFTS: 38

Soft Tissue Sarcoma

Categories: Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Soft Tissue Sarcoma

MalaCards integrated aliases for Soft Tissue Sarcoma:

Name: Soft Tissue Sarcoma 19 58 28 41 16
Non-Rhabdomyosarcoma Soft Tissue Sarcoma 19
Malignant Mesenchymal Tumor 58
Malignant Soft Tissue Tumor 58
Connective Tissue Sarcoma 19
Soft-Tissue Sarcoma 75
Soft Part Sarcoma 58
Sarcoma 71

Characteristics:


Prevelance:

1-9/100000 (France, Europe) 1-5/10000 (Europe) 58

Classifications:



External Ids:

UMLS via Orphanet 72 C0334492 C1261473
Orphanet 58 ORPHA3394
UMLS 71 C1261473

Summaries for Soft Tissue Sarcoma

GARD: 19 Soft tissue sarcoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of the "soft tissues" of the body. These tissues connect, support and surround other body parts and may include muscle, fat, blood vessels, lymph vessels, nerves, tendons and the lining of joints. Many people with early Soft tissue sarcoma have no signs or symptoms of the condition. When present, symptoms depend on the location and size of the tumor but may include a palpable lump under the skin, pain, or difficulty breathing. Most cases occur sporadically in people with little to no family history of the condition. People who have previously received radiation therapy and those with certain inherited disorders (such as Gorlin syndrome, Gardner syndrome, Li-Fraumeni syndrome, Tuberous sclerosis, neurofibromatosis type 1, and Werner syndrome) have an increased risk of developing a Soft tissue sarcoma.

MalaCards based summary: Soft Tissue Sarcoma, also known as non-rhabdomyosarcoma soft tissue sarcoma, is related to alveolar soft part sarcoma and sarcoma. The drugs Lopinavir and Lamivudine have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and uterus.

MedlinePlus: 41 Your soft tissues connect, support, or surround other tissues. Examples include your muscles, tendons, fat, and blood vessels. Soft tissue sarcoma is a cancer of these soft tissues. There are many kinds, based on the type of tissue they started in. They may cause a lump or swelling in the soft tissue. Sometimes they spread and can press on nerves and organs, causing problems such as pain or trouble breathing. No one knows exactly what causes these cancers. They are not common, but you have a higher risk if you have been exposed to certain chemicals, have had radiation therapy, or have certain genetic diseases. Doctors diagnose soft tissue sarcomas with a biopsy. Treatments include surgery to remove the tumor, radiation therapy, chemotherapy, or a combination. NIH: National Cancer Institute

Wikipedia: 75 A soft-tissue sarcoma (STS) is a malignant tumour, a type of cancer, that develops in soft tissue. A... more...

Related Diseases for Soft Tissue Sarcoma

Diseases related to Soft Tissue Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 540)
# Related Disease Score Top Affiliating Genes
1 alveolar soft part sarcoma 11.7
2 sarcoma 11.7
3 cervical alveolar soft part sarcoma 11.7
4 vulvar alveolar soft part sarcoma 11.7
5 short stature, onychodysplasia, facial dysmorphism, and hypotrichosis 11.6
6 sarcoma, synovial 11.6
7 dermatofibrosarcoma protuberans 11.5
8 leiomyosarcoma 11.4
9 liposarcoma 11.4
10 sarcoma of cervix uteri 11.4
11 hemangiopericytoma, malignant 11.3
12 gastrointestinal stromal tumor 11.3
13 rhabdoid cancer 11.3
14 malignant peripheral nerve sheath tumor 11.3
15 bone sarcoma 11.3
16 myxoid liposarcoma 11.3
17 muscle cancer 11.3
18 epithelioid sarcoma 11.3
19 myxofibrosarcoma 11.3
20 embryonal rhabdomyosarcoma 11.3
21 gallbladder sarcoma 11.2
22 chondrosarcoma, extraskeletal myxoid 11.2
23 mesenchymal chondrosarcoma 11.2
24 leiomyosarcoma of the cervix uteri 11.2
25 pleomorphic rhabdomyosarcoma 11.2
26 clear cell chondrosarcoma 11.1
27 heart malignant hemangiopericytoma 11.1
28 connective tissue disease 11.1
29 bednar tumor 11.1
30 malignant peripheral nerve sheath tumor with perineurial differentiation 11.1
31 vulvovaginal rhabdomyosarcoma 11.1
32 rhabdomyosarcoma of the corpus uteri 11.1
33 rhabdomyosarcoma of the cervix uteri 11.1
34 rhabdomyosarcoma 11.1
35 malignant fibrous histiocytoma 11.0
36 factor vii deficiency 11.0
37 fibrous histiocytoma 10.9
38 cutaneous fibrous histiocytoma 10.9
39 fibrosarcoma 10.9
40 neutropenia 10.9
41 ewing sarcoma 10.9
42 angiosarcoma 10.9
43 osteogenic sarcoma 10.8
44 rhabdomyosarcoma 2 10.7
45 retroperitoneal sarcoma 10.7
46 chondrosarcoma 10.7
47 mesenchymal cell neoplasm 10.7
48 dedifferentiated liposarcoma 10.6
49 adult syndrome 10.6
50 mucositis 10.6

Graphical network of the top 20 diseases related to Soft Tissue Sarcoma:



Diseases related to Soft Tissue Sarcoma

Symptoms & Phenotypes for Soft Tissue Sarcoma

Drugs & Therapeutics for Soft Tissue Sarcoma

Drugs for Soft Tissue Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 528)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lopinavir Approved Phase 4 192725-17-0 92727
2
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
3
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
4
Racivir Approved, Investigational Phase 4 143491-57-0, 143491-54-7 60877
5
Bleomycin Approved, Investigational Phase 4 9041-93-4, 11056-06-7 5360373
6
Nevirapine Approved Phase 4 129618-40-2 4463
7
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
8
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
9
Tranexamic acid Approved Phase 4 1197-18-8 5526
10
Reviparin Approved, Investigational Phase 4 9041-08-1
11
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
12
Tenofovir Experimental, Investigational Phase 4 147127-20-6, 202138-50-9 464205 6398764
13 Cytochrome P-450 Enzyme Inhibitors Phase 4
14 Cytochrome P-450 CYP3A Inhibitors Phase 4
15 Reverse Transcriptase Inhibitors Phase 4
16 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
17 Stavudine, lamivudine, nevirapine drug combination Phase 4
18 Antifibrinolytic Agents Phase 4
19 Hemostatics Phase 4
20 Coagulants Phase 4
21 Calcineurin Inhibitors Phase 4
22 Heparin, Low-Molecular-Weight Phase 4
23 Antipyretics Phase 4
24 Platelet Aggregation Inhibitors Phase 4
25
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
26
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
27
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
28
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
29
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5, 188062-50-2 441300
30
Zidovudine Approved Phase 2, Phase 3 30516-87-1 35370
31
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
32
Olaparib Approved Phase 3 763113-22-0 23725625
33
Ceritinib Approved Phase 3 1032900-25-6 57379345
34
Lapatinib Approved, Investigational Phase 3 231277-92-2, 388082-78-8 208908
35
Trametinib Approved Phase 3 871700-17-3 11707110
36
Futibatinib Approved, Investigational Phase 3 1448169-71-8 71621331
37
Dabrafenib Approved, Investigational Phase 3 1195765-45-7 44462760
38
Panitumumab Approved, Investigational Phase 3 339177-26-3
39
Trifluridine Approved, Investigational Phase 3 70-00-8 6256
40
Plasminogen Approved Phase 3 9001-91-6
41
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239
42
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
43
Daunorubicin Approved Phase 3 20830-81-3 30323
44
Epirubicin Approved Phase 3 56420-45-2 41867
45
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
46
Picropodophyllin Approved, Investigational Phase 3 518-28-5, 477-47-4 10607 72435
47
Mitoxantrone Approved, Investigational Phase 3 70476-82-3, 65271-80-9 4212
48 Grape Approved Phase 3
49 Cranberry Approved, Investigational Phase 3
50
Cytarabine Approved, Investigational Phase 3 147-94-4 6253

Interventional clinical trials:

(show top 50) (show all 1683)
# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma Completed NCT03514381 Phase 4 Patients starting a treatment with Doxorubicin and Ifosfamide
3 Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule Completed NCT04223583 Phase 4 Anlotinib Hydrochloride
4 A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
5 A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
6 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
7 An Open Label, Single Centre, Single Arm, Prospective Feasibility Study Evaluating the Effectiveness of Near-infrared Fluorescence (NIRF) Using Indo-cyanine Green (ICG) in Minimally Invasive Paediatric Oncology Surgery (MIS) Recruiting NCT04854018 Phase 4 Indocyanine green
8 Prospective, Randomized Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Recruiting NCT03144206 Phase 4 Hyperbaric oxygen
9 Registry of Retroperitoneal, Abdominal, Pelvic and Truncal Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® to Evaluate the Safety and Feasibility Over 5 Years Recruiting NCT04033081 Phase 4
10 Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction: A Randomized Controlled Trial Recruiting NCT04347122 Phase 4 Tranexamic Acid (TXA)
11 Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial Recruiting NCT04077515 Phase 4 Sirolimus(0.8mg/m2);Sirolimus(0.7mg/m2)
12 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
13 Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma: a Randomized Controlled Trial Recruiting NCT04448873 Phase 4 Sirolimus
14 Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
15 Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib - a Randomized, Controlled Trial Terminated NCT03735758 Phase 4 pazopanib or guideline conform chemotherapy
16 Phase III Study of Preoperative vs Postoperative Intensity Modulated Radiation Therapy For Truncal/Extremity Soft Tissue Sarcoma Unknown status NCT02565498 Phase 3
17 A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma Unknown status NCT02449343 Phase 2, Phase 3 Anlotinib;Placebo
18 Assessment of the Effect of a Co-treatment With GnRH Analogs on the Ovarian Reserve in Adolescents and Young Women Treated With Alkylating Agents for Cancer Unknown status NCT02856048 Phase 2, Phase 3 Triptorelin (GnRHa) + Chemotherapy
19 EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92] Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
20 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
21 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
22 A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005] Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
23 European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99) Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
24 Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
25 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
26 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
27 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
28 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
29 Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma Completed NCT00003958 Phase 3 vincristine sulfate;cyclophosphamide;topotecan hydrochloride
30 A Randomized Phase III Trial Comparing Trabectedin (Yondelis®) to the Best Supportive Care in Patients With Advanced Soft Tissue Sarcoma Completed NCT02672527 Phase 3 Trabectedin;Dexamethasone
31 A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
32 A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults Completed NCT00876031 Phase 3 trofosfamide, idarubicin, etoposide
33 A Multicenter Randomized, Open-Label Phase II/III Study, To Compare The Efficacy Of NBTXR3, Implanted As Intratumor Injection And Activated By Radiotherapy, Versus Radiotherapy Alone In Patients With Locally Advanced Soft Tissue Sarcoma Of The Extremity And Trunk Wall Completed NCT02379845 Phase 2, Phase 3
34 A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
35 A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3 Eribulin mesylate 1.4 mg/m^2 intravenous;Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
36 A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma. Completed NCT01168791 Phase 3 doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo
37 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
38 A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies. Completed NCT00699517 Phase 3 OMBRABULIN (AVE8062);Placebo
39 A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
40 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
41 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
42 Ph III Random Trial of 120-Min Infusion Gemcitabine v. 90-Min Infusion Gemcitabine + Docetaxel in Unresectable Soft Tissue Sarcoma: A Multi-Disciplinary Trial of the North Amer. Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
43 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
44 A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma Completed NCT00001300 Phase 3 doxorubicin;ifosfamide;mesna
45 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
46 A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III Completed NCT00002706 Phase 3
47 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
48 Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma. Completed NCT02063022 Phase 3 Standard treatment (as per protocol ISG SSG III);Intensified chemotherapy
49 A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma Completed NCT00002445 Phase 3 IM862
50 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed NCT00002093 Phase 3 Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride

Search NIH Clinical Center for Soft Tissue Sarcoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ifosfamide
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa

Genetic Tests for Soft Tissue Sarcoma

Genetic tests related to Soft Tissue Sarcoma:

# Genetic test Affiliating Genes
1 Soft Tissue Sarcoma 28

Anatomical Context for Soft Tissue Sarcoma

Organs/tissues related to Soft Tissue Sarcoma:

MalaCards : Bone, T Cells, Uterus, Skin, Bone Marrow, Lung, Myeloid

Publications for Soft Tissue Sarcoma

Articles related to Soft Tissue Sarcoma:

(show top 50) (show all 9728)
# Title Authors PMID Year
1
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306. 62 41
35871234 2022
2
A Case-Control Study of the Effects of Implementing the Registered Nurses' Association of Ontario Guidelines for the Assessment and Management of Postoperative Pain and the Use of Relaxation Therapy in 312 Patients with Bone and Soft-Tissue Malignancy. 41
36097401 2022
3
Development and validation of a prognostic nomogram for adult patients with renal sarcoma: A retrospective study based on the SEER database. 41
36187680 2022
4
Alveolar Soft Part Sarcoma of Hypopharynx; A Case Report. 62
33320015 2023
5
Evidence for the Current Management of Soft-tissue Sarcoma and Gastrointestinal Stromal Tumors and Emerging Directions. 62
36410916 2023
6
Complete response of metastatic alveolar soft part sarcoma in an adolescent female treated by combined immune checkpoint inhibitors. 62
35593032 2022
7
Retro-orbital alveolar soft-part sarcoma in a 76-year-old female: case report and review of the literature. 62
35472298 2022
8
Primary Alveolar Soft Part Sarcoma of Bone: A Rare Occurrence in 8 Patients, Posing a Diagnostic Challenge. 62
35438716 2022
9
Managing patients with advanced soft tissue sarcoma: Evolving landscape from an Australian perspective. 62
35098667 2022
10
What's the latest with investigational drugs for soft tissue sarcoma? 62
36424693 2022
11
Subcutaneous entomophthoromycosis in an immunocompetent individual: a localised forearm swelling. 62
36455985 2022
12
Myositis ossificans circumscripta after surgery and radiotherapy and during sunitinib treatment: a case report. 62
36474288 2022
13
Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk. 62
36153202 2022
14
Doxorubicin-Loaded Polymeric Meshes Prevent Local Recurrence after Sarcoma Resection While Avoiding Cardiotoxicity. 62
36169924 2022
15
Inflammatory prognostic scoring systems are risk factors for surgical site infection following wide local excision of soft tissue sarcoma. 62
34628535 2022
16
Long-term experience with intraoperative electron radiation therapy boost in extremity sarcoma. 62
35856506 2022
17
Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma. 62
36464833 2022
18
Optimization of the preoperative requirements of blood units for the surgical treatment of extra-abdominal soft tissue sarcoma: the TRANSAR score. 62
36464677 2022
19
Rhabdomyosarcoma with unknown primary tumor site: A report from European pediatric Soft tissue sarcoma Study Group (EpSSG). 62
36094298 2022
20
Complete Response to Eribulin in a Patient with Unresectable Liposarcoma: A Case Report and Implications of New Biomarkers. 62
35527027 2022
21
A flexible-hazards cure model with application to patients with soft tissue sarcoma. 62
36165535 2022
22
Preoperative hypofractionated radiotherapy for soft tissue sarcoma. 62
36455570 2022
23
Whole-tumor histogram analysis of diffusion-weighted imaging and dynamic contrast-enhanced MRI for soft tissue sarcoma: correlation with HIF-1alpha expression. 62
36462043 2022
24
MRI-Based Computer-Aided Diagnostic Model to Predict Tumor Grading and Clinical Outcomes in Patients With Soft Tissue Sarcoma. 62
35303756 2022
25
Clinical-Radiomics Nomogram from T1W, T1CE, and T2FS MRI for Improving Diagnosis of Soft-Tissue Sarcoma. 62
35799035 2022
26
Diagnostic Performance of Dynamic Contrast-Enhanced MRI and 18F-FDG PET/CT for Evaluation of Soft Tissue Tumors and Correlation with Pathology Parameters. 62
35396157 2022
27
ISA-Net: Improved spatial attention network for PET-CT tumor segmentation. 62
36156438 2022
28
circCsnk1g3- and circAnkib1-regulated interferon responses in sarcoma promote tumorigenesis by shaping the immune microenvironment. 62
36433954 2022
29
Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma. 62
35850363 2022
30
Age-adjusted Charlson Comorbidity Index is a valuable prognostic tool in operable soft tissue sarcoma of trunk and extremities. 62
36455864 2022
31
A contrast-enhanced MRI-based nomogram to identify lung metastasis in soft-tissue sarcoma: A multi-centre study. 62
36433749 2022
32
Surgical treatment of undifferentiated soft tissue sarcoma in a young 17-year-old woman: A case report. 62
36334549 2022
33
Therapeutic perspectives for adult soft tissue sarcoma-updates from the 2022 ASCO annual meeting. 62
36350007 2022
34
ASO Author Reflections: A Call for Consensus, Collaboration and Data on the Role of Sentinel Lymph Node Biopsy for Soft Tissue Sarcoma. 62
36394686 2022
35
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032). 62
36396869 2022
36
KIF20A promotes the development of fibrosarcoma via PI3K-Akt signaling pathway. 62
36037925 2022
37
Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. 62
36322658 2022
38
Liver metastasis in soft tissue sarcoma at initial presentation. 62
35791961 2022
39
Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients using Deep Learning of H&E Images: A Report from the Children's Oncology Group. 62
36346688 2022
40
Long-term Follow-up of Detaenial Sigmoid Neobladder Reconstruction for Paediatric Patients with Bladder and Prostate Rhabdomyosarcoma: Technique and Results from a Single High-volume Centre. 62
36050131 2022
41
Malignant ectomesenchymoma in children: The European pediatric Soft tissue sarcoma Study Group experience. 62
36440693 2022
42
Pazopanib for treating rhabdomyosarcoma in adult patients with poor performance status: A case report. 62
36131227 2022
43
Biomolecular interaction mechanism of an anticancer drug, pazopanib with human serum albumin: a multi-spectroscopic and computational approach. 62
33870854 2022
44
Non-coding RNAs in drug and radiation resistance of bone and soft-tissue sarcoma: a systematic review. 62
36326232 2022
45
Personalized Surgical Planning for Soft Tissue Sarcoma of the Popliteal Fossa with a Novel 3D Imaging Technique. 62
36128857 2022
46
Creating a data commons: The INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT). 62
35969120 2022
47
[Extremity soft tissue sarcoma: does surgical margin impact survival?] 62
36423355 2022
48
Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells. 62
36430780 2022
49
Shortening the Time Interval for the Referral of Patients With Soft Tissue Sarcoma to Expert Centers Using Mobile Health: Retrospective Study. 62
36350680 2022
50
Mortality patterns of soft-tissue sarcomas worldwide up to 2018, with predictions for 2025. 62
36346699 2022

Variations for Soft Tissue Sarcoma

Expression for Soft Tissue Sarcoma

Search GEO for disease gene expression data for Soft Tissue Sarcoma.

Pathways for Soft Tissue Sarcoma

GO Terms for Soft Tissue Sarcoma

Sources for Soft Tissue Sarcoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....